 |
|
 LATEST NEWS |
| |
| METABOLEX AND SANOFI-AVENTIS ENTER INTO AN AGREEMENT FOR NOVEL TYPE 2 DIABETES TREATMENT |
|
| June 25, 2010 |
|
| Metabolex and Sanofi-Aventis announced today that they have entered into a global license and development agreement for the research, development, manufacture and commercialization of small molecules that modulate the G-protein coupled receptor 119 (GPR119), a receptor in the gut and pancreas that interacts with bioactive lipids to stimulate glucose-dependent incretin and insulin secretion. |
| |
|
More > |
| |
| METABOLEX ENTERS INTO TYPE 2 DIABETES DEVELOPMENT AND LICENSE AGREEMENT |
|
| June 22, 2010 |
|
| Metabolex, Inc. announced today that they have entered into a global development and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) to further develop and discover compounds for the treatment of type 2 diabetes and other disorders. |
| |
|
More > |
| |
| METABOLEX INITIATES RESEARCH COLLABORATION WITH TAKEDA |
|
| April 13, 2010 |
|
| Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today the initiation of a research collaboration with Takeda San Francisco, Inc. (TSF), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. |
| |
|
More > |
| |
|
